Value of shared preclinical safety studies - The eTOX database

Area of Science:

• Pharmacology and Toxicology
• Computational Chemistry
• Drug Safety

Background:

• Preclinical safety data is crucial for drug development.
• Sharing data across pharmaceutical companies can enhance safety assessments.
• The eTOX project aims to consolidate and analyze such data.

Purpose of the Study:

• To analyze a large database of preclinical safety data for small molecule drugs.
• To assess the feasibility of building in silico predictive models using this data.
• To evaluate the utility of the data for understanding treatment-related effects and toxicity biomarkers.

Main Methods:

• Analysis of a database containing 3970 reports from 13 pharmaceutical companies.
• Examination of species, duration of exposure, and administration route for data homogeneity.
• Utilizing the eTOX ontology to categorize clinical chemistry and histopathology findings.
• Mining data to assess the sensitivity of in vivo biomarkers for liver toxicity.

Main Results:

• A comprehensive analysis of preclinical safety data for 1214 small molecule drugs and candidates.
• Identified common treatment-related clinical chemistry and histopathology findings.
• Evaluated the potential for creating robust in silico predictive models.
• Assessed the sensitivity of established in vivo biomarkers for liver toxicity risk.

Conclusions:

• The shared preclinical safety database is valuable for in silico model development.
• The data can inform early drug development and toxicity risk assessment.
• Further analysis can enhance predictive toxicology and drug safety evaluations.